Switch to:
Also traded in: Germany, Japan

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ALPMY's Cash to Debt is ranked higher than
94% of the 761 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.33 vs. ALPMY: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ALPMY' s Cash to Debt Range Over the Past 10 Years
Min: 44.31  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.70
ALPMY's Equity to Asset is ranked higher than
62% of the 704 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.63 vs. ALPMY: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
ALPMY' s Equity to Asset Range Over the Past 10 Years
Min: 0.7  Med: 0.77 Max: 0.81
Current: 0.7
0.7
0.81
Interest Coverage 149.71
ALPMY's Interest Coverage is ranked higher than
71% of the 475 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.69 vs. ALPMY: 149.71 )
Ranked among companies with meaningful Interest Coverage only.
ALPMY' s Interest Coverage Range Over the Past 10 Years
Min: 60.32  Med: 818.52 Max: 9999.99
Current: 149.71
60.32
9999.99
F-Score: 8
Z-Score: 6.09
M-Score: -2.67
WACC vs ROIC
4.37%
19.51%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 8/10

vs
industry
vs
history
Operating margin (%) 18.14
ALPMY's Operating margin (%) is ranked higher than
79% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.73 vs. ALPMY: 18.14 )
Ranked among companies with meaningful Operating margin (%) only.
ALPMY' s Operating margin (%) Range Over the Past 10 Years
Min: 10.25  Med: 16.72 Max: 28.37
Current: 18.14
10.25
28.37
Net-margin (%) 14.11
ALPMY's Net-margin (%) is ranked higher than
78% of the 710 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.01 vs. ALPMY: 14.11 )
Ranked among companies with meaningful Net-margin (%) only.
ALPMY' s Net-margin (%) Range Over the Past 10 Years
Min: 7.09  Med: 11.72 Max: 18.24
Current: 14.11
7.09
18.24
ROE (%) 14.77
ALPMY's ROE (%) is ranked higher than
74% of the 742 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.15 vs. ALPMY: 14.77 )
Ranked among companies with meaningful ROE (%) only.
ALPMY' s ROE (%) Range Over the Past 10 Years
Min: 6.52  Med: 10.93 Max: 16.06
Current: 14.77
6.52
16.06
ROA (%) 10.84
ALPMY's ROA (%) is ranked higher than
81% of the 766 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.68 vs. ALPMY: 10.84 )
Ranked among companies with meaningful ROA (%) only.
ALPMY' s ROA (%) Range Over the Past 10 Years
Min: 5.01  Med: 8.24 Max: 12.27
Current: 10.84
5.01
12.27
ROC (Joel Greenblatt) (%) 71.44
ALPMY's ROC (Joel Greenblatt) (%) is ranked higher than
91% of the 759 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 14.13 vs. ALPMY: 71.44 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ALPMY' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: 30.35  Med: 57.05 Max: 87.46
Current: 71.44
30.35
87.46
Revenue Growth (3Y)(%) 13.20
ALPMY's Revenue Growth (3Y)(%) is ranked higher than
72% of the 601 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 5.60 vs. ALPMY: 13.20 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ALPMY' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 1.50 Max: 13.2
Current: 13.2
0
13.2
EBITDA Growth (3Y)(%) 24.60
ALPMY's EBITDA Growth (3Y)(%) is ranked higher than
78% of the 553 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.40 vs. ALPMY: 24.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ALPMY' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -6.65 Max: 24.6
Current: 24.6
0
24.6
EPS Growth (3Y)(%) 35.50
ALPMY's EPS Growth (3Y)(%) is ranked higher than
83% of the 510 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.30 vs. ALPMY: 35.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ALPMY' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 3.70 Max: 54.3
Current: 35.5
0
54.3
» ALPMY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with ALPMY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare:OTCPK:OTSKY, OTCPK:CHGCY, OTCPK:OPHLY, OTCPK:DSNKY, OTCPK:KYKOF, OTCPK:SNPHF, OTCPK:CHJTF, OTCPK:PTKFF, OTCPK:GWPRF, OTCPK:MAYNF, NAS:HCM, AMEX:TXMD, OTCPK:HAWPF, OTCPK:DCHPF, OTCPK:VEGPF, OTCPK:SKYEY, NAS:RTRX, OTCPK:ULIHF, OTCPK:ABSCF, NAS:AERI » details
Traded in other countries:YPH.Germany, 4503.Japan,
Astellas Pharma Inc and its subsidiaries are engaged in manufacturing, marketing and import/export of pharmaceuticals. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs.

Astellas Pharma Inc was incorporated on March 20, 1939. The Company and its subsidiaries are engaged in the manufacturing, marketing of pharmaceuticals products. It develops products in the areas of urology, immunology and allergy, cardiovascular, diabetes, gastrointestinal and motor organs. Its products include Prograf, an immunosuppressant to prevent rejection in organ transplants; Protopic for the treatment of atopic dermatitis in the topical immunomodulator class; Vesicare, a treatment for overactive bladder; Harnal, an a1 blocking agent for the treatment of benign prostatic hyperplasia; and Funguard, a candin antifungal agent. The Company's products also comprise Geninax, an oral quinolone antibacterial agent; Celecox, a selective COX-2 inhibitor; Lipitor, a treatment for hypercholesterolemia; Micardis, a treatment hypertension; Gaster, a treatment for peptic ulcers and gastritis; Myslee, a hypnotic; Cefzon, an oral cephalosporin; Seroquel, an antipsychotic agent; Dorner, a treatment for chronic arterial occlusion; Nasea, an antagonist; Regnite, a treatment for restless legs syndrome; and Kiklin, a treatment for hyperphatemia. The Company also offers Lexiscan and Adenoscan, which are pharmacologic stress agents; Tarceva, a treatment for non-small cell lung cancer; Vaprisol, a treatment for euvolemic hyponatremia; AmBisome, a systemic antifungal agent; Eligard, a treatment for advanced prostate cancer; Locoid, a topical corticosteroid; Zineryt, a treatment for acne; Locobase, a treatment for dry skin; and Dificlir, a novel treatment for CDI.

Ratios

vs
industry
vs
history
P/E(ttm) 18.56
ALPMY's P/E(ttm) is ranked higher than
72% of the 593 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.41 vs. ALPMY: 18.56 )
Ranked among companies with meaningful P/E(ttm) only.
ALPMY' s P/E(ttm) Range Over the Past 10 Years
Min: 3.3  Med: 14.66 Max: 34.45
Current: 18.56
3.3
34.45
PE(NRI) 18.56
ALPMY's PE(NRI) is ranked higher than
73% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 28.39 vs. ALPMY: 18.56 )
Ranked among companies with meaningful PE(NRI) only.
ALPMY' s PE(NRI) Range Over the Past 10 Years
Min: 3.3  Med: 14.66 Max: 34.45
Current: 18.56
3.3
34.45
Price/Owner Earnings (ttm) 26.41
ALPMY's Price/Owner Earnings (ttm) is ranked higher than
62% of the 282 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 34.57 vs. ALPMY: 26.41 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALPMY' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.69  Med: 28.10 Max: 85.74
Current: 26.41
5.69
85.74
P/B 2.81
ALPMY's P/B is ranked higher than
51% of the 823 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.89 vs. ALPMY: 2.81 )
Ranked among companies with meaningful P/B only.
ALPMY' s P/B Range Over the Past 10 Years
Min: 1.27  Med: 1.89 Max: 3.37
Current: 2.81
1.27
3.37
P/S 2.64
ALPMY's P/S is ranked higher than
52% of the 767 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.74 vs. ALPMY: 2.64 )
Ranked among companies with meaningful P/S only.
ALPMY' s P/S Range Over the Past 10 Years
Min: 0.55  Med: 1.74 Max: 11.08
Current: 2.64
0.55
11.08
PFCF 18.42
ALPMY's PFCF is ranked higher than
58% of the 221 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.52 vs. ALPMY: 18.42 )
Ranked among companies with meaningful PFCF only.
ALPMY' s PFCF Range Over the Past 10 Years
Min: 14.32  Med: 26.77 Max: 81.3
Current: 18.42
14.32
81.3
POCF 11.49
ALPMY's POCF is ranked higher than
71% of the 292 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.35 vs. ALPMY: 11.49 )
Ranked among companies with meaningful POCF only.
ALPMY' s POCF Range Over the Past 10 Years
Min: 9.1  Med: 16.88 Max: 56.41
Current: 11.49
9.1
56.41
EV-to-EBIT 11.50
ALPMY's EV-to-EBIT is ranked higher than
75% of the 591 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 21.71 vs. ALPMY: 11.50 )
Ranked among companies with meaningful EV-to-EBIT only.
ALPMY' s EV-to-EBIT Range Over the Past 10 Years
Min: 0.7  Med: 10.95 Max: 26.2
Current: 11.5
0.7
26.2
EV-to-EBITDA 9.12
ALPMY's EV-to-EBITDA is ranked higher than
79% of the 625 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 16.97 vs. ALPMY: 9.12 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALPMY' s EV-to-EBITDA Range Over the Past 10 Years
Min: 0.7  Med: 8.35 Max: 19
Current: 9.12
0.7
19
PEG 1.48
ALPMY's PEG is ranked higher than
59% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.01 vs. ALPMY: 1.48 )
Ranked among companies with meaningful PEG only.
ALPMY' s PEG Range Over the Past 10 Years
Min: 1.38  Med: 2.85 Max: 4.96
Current: 1.48
1.38
4.96
Current Ratio 2.17
ALPMY's Current Ratio is ranked lower than
55% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.39 vs. ALPMY: 2.17 )
Ranked among companies with meaningful Current Ratio only.
ALPMY' s Current Ratio Range Over the Past 10 Years
Min: 2.17  Med: 3.13 Max: 5.5
Current: 2.17
2.17
5.5
Quick Ratio 1.78
ALPMY's Quick Ratio is ranked higher than
50% of the 682 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.78 vs. ALPMY: 1.78 )
Ranked among companies with meaningful Quick Ratio only.
ALPMY' s Quick Ratio Range Over the Past 10 Years
Min: 1.78  Med: 2.83 Max: 5.17
Current: 1.78
1.78
5.17
Days Inventory 170.55
ALPMY's Days Inventory is ranked lower than
74% of the 666 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 114.20 vs. ALPMY: 170.55 )
Ranked among companies with meaningful Days Inventory only.
ALPMY' s Days Inventory Range Over the Past 10 Years
Min: 118.75  Med: 136.23 Max: 173.26
Current: 170.55
118.75
173.26

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 1.80
ALPMY's Dividend Yield is ranked higher than
62% of the 603 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.48 vs. ALPMY: 1.80 )
Ranked among companies with meaningful Dividend Yield only.
ALPMY' s Dividend Yield Range Over the Past 10 Years
Min: 1.47  Med: 3.22 Max: 5.25
Current: 1.8
1.47
5.25
Dividend Payout 0.37
ALPMY's Dividend Payout is ranked lower than
53% of the 379 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.34 vs. ALPMY: 0.37 )
Ranked among companies with meaningful Dividend Payout only.
ALPMY' s Dividend Payout Range Over the Past 10 Years
Min: 0.32  Med: 0.43 Max: 0.85
Current: 0.37
0.32
0.85
Dividend Growth (3y) 7.20
ALPMY's Dividend Growth (3y) is ranked lower than
51% of the 288 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.70 vs. ALPMY: 7.20 )
Ranked among companies with meaningful Dividend Growth (3y) only.
ALPMY' s Dividend Growth (3y) Range Over the Past 10 Years
Min: 1.3  Med: 6.75 Max: 52.5
Current: 7.2
1.3
52.5
Forward Dividend Yield 1.96
ALPMY's Forward Dividend Yield is ranked higher than
62% of the 578 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.54 vs. ALPMY: 1.96 )
Ranked among companies with meaningful Forward Dividend Yield only.
N/A
Yield on cost (5-Year) 2.36
ALPMY's Yield on cost (5-Year) is ranked higher than
59% of the 707 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.93 vs. ALPMY: 2.36 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALPMY' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 1.9  Med: 4.18 Max: 6.8
Current: 2.36
1.9
6.8
3-Year Average Share Buyback Ratio 2.00
ALPMY's 3-Year Average Share Buyback Ratio is ranked higher than
96% of the 422 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -4.10 vs. ALPMY: 2.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALPMY' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -12.8  Med: 2.40 Max: 0
Current: 2
-12.8
0

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 9.85
ALPMY's Price/Net Current Asset Value is ranked lower than
62% of the 552 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.25 vs. ALPMY: 9.85 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ALPMY' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 2.2  Med: 4.50 Max: 8.9
Current: 9.85
2.2
8.9
Price/Tangible Book 4.57
ALPMY's Price/Tangible Book is ranked lower than
60% of the 765 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 3.59 vs. ALPMY: 4.57 )
Ranked among companies with meaningful Price/Tangible Book only.
ALPMY' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.46  Med: 2.29 Max: 4.87
Current: 4.57
1.46
4.87
Price/Projected FCF 1.87
ALPMY's Price/Projected FCF is ranked higher than
60% of the 344 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.59 vs. ALPMY: 1.87 )
Ranked among companies with meaningful Price/Projected FCF only.
ALPMY' s Price/Projected FCF Range Over the Past 10 Years
Min: 1.69  Med: 1.92 Max: 2.33
Current: 1.87
1.69
2.33
Price/Median PS Value 1.52
ALPMY's Price/Median PS Value is ranked lower than
69% of the 734 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.14 vs. ALPMY: 1.52 )
Ranked among companies with meaningful Price/Median PS Value only.
ALPMY' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.41  Med: 1.24 Max: 4.99
Current: 1.52
0.41
4.99
Price/Peter Lynch Fair Value 1.62
ALPMY's Price/Peter Lynch Fair Value is ranked higher than
50% of the 173 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.61 vs. ALPMY: 1.62 )
Ranked among companies with meaningful Price/Peter Lynch Fair Value only.
ALPMY' s Price/Peter Lynch Fair Value Range Over the Past 10 Years
Min: 1.46  Med: 2.24 Max: 3.86
Current: 1.62
1.46
3.86
Price/Graham Number 1.94
ALPMY's Price/Graham Number is ranked higher than
57% of the 500 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.19 vs. ALPMY: 1.94 )
Ranked among companies with meaningful Price/Graham Number only.
ALPMY' s Price/Graham Number Range Over the Past 10 Years
Min: 0.74  Med: 1.58 Max: 2.63
Current: 1.94
0.74
2.63
Earnings Yield (Greenblatt) (%) 8.65
ALPMY's Earnings Yield (Greenblatt) (%) is ranked higher than
82% of the 844 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. ALPMY: 8.65 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALPMY' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 3.8  Med: 9.15 Max: 141.9
Current: 8.65
3.8
141.9
Forward Rate of Return (Yacktman) (%) 14.09
ALPMY's Forward Rate of Return (Yacktman) (%) is ranked higher than
64% of the 325 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.60 vs. ALPMY: 14.09 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) (%) only.
ALPMY' s Forward Rate of Return (Yacktman) (%) Range Over the Past 10 Years
Min: -1.5  Med: 9.40 Max: 14.5
Current: 14.09
-1.5
14.5

More Statistics

Revenue (TTM) (Mil) $11,467
EPS (TTM) $ 0.75
Beta0.49
Short Percentage of Float0.00%
52-Week Range $12.50 - 16.67
Shares Outstanding (Mil)2,056.98
» More Articles for OTCPK:ALPMY

Headlines

Articles On GuruFocus.com
Charles De Vaulx Comments on Astellas Pharma Inc. Jun 06 2016 
Charles de Vaulx's Annual IVA Funds Letter from the Portfolio Managers Jun 06 2016 
IVA Worldwide Fund Quarterly Review - Fourth Quarter 2015 Jan 22 2016 
Astellas Pharma: Outstanding Growth, Undervalued Dec 14 2015 
Astellas Pharma Has Been Growing for Years and Is Underpriced Dec 11 2015 
Charles De Vaulx's Q3 2015 IVA Worldwide Fund Commentary Oct 22 2015 
Charles de Vaulx Sells Portions of Three of His Most Valuable Stakes Jun 01 2015 
IVA International Fund Q1 2015 Review May 28 2015 
Charles de Vaulx’s IVA Worldwide Fund Q1 2015 Review May 28 2015 
Vanguard Adds to Four of Its Largest Stakes May 04 2015 

More From Other Websites
Japan is Breathing Life into the Stem Cell Space, Astellas Pharma (ALPMF) & Pluristem Therapeutics... Jul 21 2016
Excelra Enters into a Drug Repurposing Collaboration with Astellas Pharma Jun 07 2016
Seattle Genetics and Astellas Present ASG-15ME and Enfortumab Vedotin Phase I Clinical Data in... Jun 06 2016
Astellas and Seattle Genetics Present ASG-15ME and ASG-22ME Phase I Clinical Data in Metastatic... Jun 06 2016
Astellas and Medivation Initiate Phase III Trial of Enzalutamide in Patients with Triple-Negative... Jun 02 2016
ETF’s with exposure to Astellas Pharma, Inc. : May 26, 2016 May 26 2016
Thunderbolt Pharma, Inc., a Vitesse Biologics Company, Acquires Rights to BAFF/APRIL Dual Antagonist... May 24 2016
Astellas Oncology Announces Data to be Presented at 2016 ASCO Annual Meeting May 19 2016
Astellas Pharma, Inc. :ALPMY-US: Earnings Analysis: Q4, 2016 By the Numbers May 16 2016
The Story behind Medivation’s Rising Collaboration Revenue May 11 2016
Sanofi Threatens to go Hostile in Medivation Battle May 05 2016
Medivation/Astellas' Xtandi Gets CHMP Nod to Include Data Apr 08 2016
CHMP Issues Positive Opinion to Include New Data in European Label for XTANDI® (enzalutamide) Apr 07 2016
Makers of pricey prostate cancer drug Xtandi are targeted by Congress Mar 29 2016
Medivation Prostate Cancer Drug Xtandi under Pricing Attack Mar 29 2016
Shares of a small drugmaker tanked after it became the target of Congress' fight against high drug... Mar 29 2016
Pivotal Phase III Trial of enzalutamide Initiated in Metastatic Hormone Sensitive Prostate Cancer Mar 24 2016
Technical Data Influencing the Market - Analyst Notes on CUBA Beverage, Arch Therapeutics, Wolseley... Mar 09 2016
Ironwood Pharmaceuticals Announces Filing by Astellas of New Drug Application in Japan with... Feb 24 2016
FDA Accepts For Review Supplemental New Drug Application for XTANDI® (enzalutamide) Capsules in... Feb 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)